Merkel Cell Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Condition: Other Skin Disorders Interventions: Biological: Autologous T Cells modified to recognize Merkel Cell Polyomavirus (FH-MCVA2TCR); Drug: Avelumab; Radiation: Radiation Therapy Sponsor: Fred Hutchinson Cancer Research Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2018 Category: Research Source Type: clinical trials
